Japan Medical Dynamic Marketing, Inc. · TSE:7600
Japan Medical Dynamic Marketing — H1 FYE March 2024 Earnings Presentation
30 slides from Japan Medical Dynamic Marketing's earnings presentation, Nov 10, 2023
Slide 1: First Half Financial Results Briefing for the Fiscal Year Ending March 2024
JMDM Securities code：7600 First Half Financial Results Briefing for the Fiscal Year Ending March 2024 November 10, 2023 Japan Medical Dynamic Marketing, INC. Representative Director and President Toshiyuki Hironaka Copyright © Japan Medical Dynamic Marketing, INC. All Rights Reserved. JMDM
Slide 2: Notes
Notes The forward-looking statements in this document are based on information currently available to us and certain assumptions that we consider reasonable, and are not intended as a promise by us that they will be realized. Actual results may differ materially due to various factors. Our products
Slide 3: Agenda
-Agenda- 1 . Results for the First Half of FYE March 2023 P. 4 2 ． Revised Forecast for FYE March 2024 - Consolidated net sales P. 5 Compared with Full-year Financial Forecast - P.19 Previous Forecast vs Forecast this time - Consolidated Statement of Income P. 6 Comparative Analysis of Operating inc
Slide 4: Results for the First Half of FYE March 2024
Results for the First Half １． of FYE March 2024
Slide 5: Consolidated net sales 10.9 Billion yen
Consolidated net sales 10.9Billion yen * After the application of (Millions of yen) revenue recognition standards YoY +９.６% 12,000 10,000 Highest first-half 8,000 net sales in company history 6,000 YoY Change Japan + 5.6% 4,000 2,000 U.S. + 15.3% * After conversion into yen 0 16/3 17/3 18/3 19/3 20/
Slide 6: Consolidated Statement of Income
Consolidated Statement of Income FYE Mar 2024 1H YoY change FYE Mar 2023 1H Ratio to Amount of Rate of Ratio to Results Results (Millions of yen, %) sales change change sales Net sales 10,952 100.0 +962 +9.6 9,989 100.0 Cogs 3,928 35.9 +558 +16.6 3,370 33.7 SG & A 6,405 58.5 +713 +12.5 5,691 57.0 Op
Slide 7: Comparative YoY Analysis of Operating income
Comparative YoY Analysis of Operating income Operating • Deterioration in operating income due to yen depreciation and decline in income • reimbursement Price (-180 million yen) Increase in Gross income（＋520 Million yen） , Cogs deterioration（-130 Million yen） -310Million yen • Increase in SG&A（＋520
Slide 8: Consolidated Net Sales by Location/Product
Consolidated Net Sales by Location/Product FYE Mar 2024 H1 YoY change FYE Mar 2023 H1 Ratio to Amont of Ratio to Ratio to Results Results （Millions of yen , ％） sales change change sales Japan 6,129 56.0 +324 +5.6 5,805 58.1 Joint 2,361 21.6 +135 +6.1 2,226 22.3 Tauma 2,059 18.8 +137 +7.1 1,922 19.2
Slide 9: Japanese market
Japanese martket
Slide 10: Sales in Japan - Quarterly Comparison
Sales in Japan - Quarterly Comparison (Millions of yen , %) 4,000 FYE Mar 2023 FYE Mar 2024 20% 15% Change of COVIT-19 to YoY change 7.1% 10% category 5. 4.1% 5% （May 2023） 3,000 0% -5% Increase in the number of cases -10% -15% 2,000 Q1 Q2 -20% Strong sales in Japan FYE Q1 Q2 Q3 Q4 Q2 ＞ Q1 Mar 2023
Slide 11: Sales in Japan 【Artificial joint】
Sales in Japan 【Artificial joint】 (Millions of yen) 2,361Million yen Strength from THA*1 2,500 YoY+6.1% TKA*2 Strong ODEV Produts Other produts 2,000 Increase in the number of cases 1,500 Change of COVIT-19 to category 5. Double-digit growth 1,000 Hip - Entrada Knee - BKS TriMax New produc
Slide 12: Sales in Japan 【Trauma】
Sales in Japan 【Trauma】 Femoral Neck (Millions of yen) 2,059Million yen Hip fracture fixation system YoY+7.1% 2,500 Prima Hip Screw 2,000 ODEV Products Other product & 1,500 ASULOCK 1,000 Double-digit growth 500 0 15/3 16/3 17/3 18/3 19/3 20/3 21/3 22/3 23/3 24/3 H1 H1 H1 H1 H1 H1 H1 H1 H1 H1 12
Slide 13: Sales in Japan 【Spine】
Sales in Japan 【Spine】 (Millions of yen) 1,635Million yen Lynx high-growth YoY+2.4% 1,500 BKP regrowth ODEV Prodcuts Other product 1,000 500 （KMC Kyphoplasty System） （ Lｙnx Plate ） 0 15/3 16/3 17/3 18/3 19/3 20/3 21/3 22/3 23/3 24/3 H1 H1 H1 H1 H1 H1 H1 H1 H1 H1 13
Slide 14: U.S. markets
U.S. markets
Slide 15: Sales in U.S.
Sales in U.S. (Millions of dollars) 35 YoY +8.9% $34.1M 30 Highest sales in the 25 first half of the year 20 Customers acquired in 15 the previous year Contributed to sales 10 expansion 5 0 15/3 16/3 17/3 18/3 19/3 20/3 21/3 22/3 23/3 24/3 H1 H1 H1 H1 H1 H1 H1 H1 H1 H1 15
Slide 16: Sales in U.S. - Quarterly Comparison
Sales in U.S. - Quarterly Comparison （Million of dollars , %） 30 20% Strong sales in U.S. FYE Mar 2023 Q2 ＞ Q1 FYE Mar 2024 YoY change 13.3% 15% 10% 20 4.8% 5% 0% Q1：YoY ＋4.8％ 10 -5% Q2：YoY＋13.3％ UHKAS held -10% -15% 0 -20% ODEV‘s seminar held every other year Q1 Q2 (in April 2023) FYE Q1 Q2 Q3 Q4 M
Slide 17: Sales in U.S. – Artificial joints, by product
Sales in U.S. – Artificial joints, by product Knee $22.6M YoY ＋16.6% Knee Hip （Q1+12.8%、Q2+20.6%） Double-digit growth in existing products. （Million of dollars） BKS TriMax 20 BKS Revision Knee New product alpha launched 15 BKS Uni Nationwide expansion in the second half of the year 10 Hip $11.
Slide 18: Forecast for the Fiscal Year Ending March 2024
Forecast for the Fiscal Year ２． Ending March 2024
Slide 19: Compared with Full-year Financial Forecast - Previous Forecast vs Forecast this time
Compared with Full-year Financial Forecast - Previous Forecast vs Forecast this time Operating income revised to 1.8 billion yen due to lower sales forecast in both Japan and U.S.A and accelerated yen depreciation. FYE March 2024 Change from initial forecast FYE March 2024 （Millions of yen , ％） Revi
Slide 20: Comparative Analysis of Operating income - Previous forecast vs Forecast this time
Comparative Analysis of Operating income - Previous forecast vs Forecast this time ・ Foreign exchange impact of changing the assumed exchange rate for the second half of the year Operating income from 135 yen to 150 yen per U.S. dollar (-240 Million) -700Million yen ・ Decrease in gross income due to
Slide 21: Revised Full-year Forecast Consolidated Statement of Income
Revised Full-year Forecast Consolidated Statement of Income Expect increase in cases YoY, but expect increase in sales and decrease in income due to yen depreciation, supply chain issues, and decline in reimbursement price FYE Mar 2024 YoY change FYE Mar 2023 Ratio to Amount of Ratio of Ratio to For
Slide 22: Compared with Previous Full-year Financial Forecast by Location/Product
Compared with Previous Full-year Financial Forecast by Location/Product Positive growth is expected in all product categories due to an increase in cases acquired in both Japan and U.S.A FYE Mar 2024 YoY change FYE Mar 2023 Ratio to Amount of Ratio to Ratio to Forecast Results （Millions of yen ,％） s
Slide 23: Strategy for the Second Half
Strategy for the Second Half Aim to expand sales of focused products and increase sales through new products in both Japan and U.S.A Reduce manufacturing costs by improving supply chain issues and reviewing external vendors. JMDM ODEV • Expand sales of products for Femoral Neck • Expand customer bas
Slide 24: Topic
3． Topic
Slide 25: Entered Regenerative medicine field - Knee joint
Topic Entered Regenerative medicine field - Knee joint Launched PRP-FD, a product for early treatment of knee joints, to medical facilities. Product name：LC-PRP （Lyophilized Concentrated PRP） What is PRP (platelet-rich plasma)? • Centrifuge the collected blood and concentrate platelets. • This treat
Slide 26: Contributing to Medical Care Through the Development and Sale of Advanced Medical Devices
Contributing to Medical Care Through the Development and Sale of Advanced Medical Devices. Japan Medical Dynamic Marketing,INC. E-MAIL WEB SITE Investor Relations Office ir@jmdm.co.jp https://www.jmdm.co.jp/en/
Slide 27: Notes
Notes
Slide 28: Selected as a constituent of the FTSE Japan Equity ESG Index
Selected as a constituent of the FTSE Japan Equity ESG Index for the first time. We selected for the first time as a component of the FTSE Blossom Japan Sector Relative Index. We will continue to strengthen our sustainability initiatives and contribute to the development of a sustainable society by
Slide 29: Sustainability Initiatives (FYE Mar 2024)
Sustainability Initiatives (FYE Mar 2024) Category Action Sustainability Identification of materiality issues Participation in TCFD Consortium Formulation of Environmental Policy Environment TCFD (Consolidated) Disclosure of GHG emission reduction targets CDP Score Level "B-" Rating Huma
Slide 30: Status of MODE2023 Medium-Term Management Plan Progress
Status of "MODE2023" Medium-Term Management Plan Progress FYE Mar 2022 FYE Mar 2023 FYE Mar 2024 （50th） （51st） （52nd） （Millions of yen , %） Result Ratio Result Ratio Forecast Ratio / Target / Target / Target Net sales 19,193 100.0% 21,307 100.0% 23,600 100.0% / 18,700 / 20,000 / 22,000 Operating inc
Japan Medical Dynamic Marketing — H1 FYE March 2024 Earnings Presentation on 6ix